Harold N Keer

US Patent:

20120128672, May 24, 2012

Filed:

Nov 14, 2011

Appl. No.:

13/296161

Inventors:

Harold Keer - Redwood City CA, US

International Classification:

A61K 39/395
A61P 35/00

US Classification:

4241341

Abstract:

The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR) having a ligand-dependent activating mutation.

US Patent:

20140056891, Feb 27, 2014

Filed:

Jun 7, 2013

Appl. No.:

13/913292

Inventors:

Harold KEER - Redwood City CA, US

Assignee:

Five Prime Therapeutics, Inc. - South San Francisco CA

International Classification:

A61K 39/395
A61K 45/06
A61K 38/17

US Classification:

4241341

Abstract:

The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation.

US Patent:

20220387384, Dec 8, 2022

Filed:

Nov 13, 2020

Appl. No.:

17/775800

Inventors:

- Tokyo, JP
- Pleasanton CA, US
Masaki YAMADA - Ibaraki, JP
Harold KEER - Pleasanton CA, US
Aram OGANESIAN - Pleasanton CA, US

International Classification:

A61K 31/40
A61K 31/203
A61P 35/02

Abstract:

A method of treating an LSD1-related disease or disorder in a patient in need, the method comprising administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient on an administration schedule comprising daily dosing for one week or two weeks, followed by a resting period of one week.

US Patent:

20200352976, Nov 12, 2020

Filed:

May 5, 2020

Appl. No.:

16/866716

Inventors:

- Tokyo, JP
Yong HAO - Dublin CA, US
Harold KEER - Emerald Hills CA, US

International Classification:

A61K 31/7084
A61K 9/00
A61P 35/02

Abstract:

Disclosed herein is a method for treating cancer with DNA-hypomethylating agents. Also disclosed herein is a method of selecting a treatment for a subject. Treatment can be given to a subject for more than one cycle of treatment to obtain improved efficacy of the treatment.

US Patent:

20150232547, Aug 20, 2015

Filed:

Nov 24, 2014

Appl. No.:

14/551782

Inventors:

- South San Francisco CA, US
Harold Keer - Redwood City CA, US

International Classification:

C07K 16/22
C07K 14/71

Abstract:

The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation.